<DOC>
	<DOCNO>NCT00283517</DOCNO>
	<brief_summary>The purpose study assess demographic , treatment , outcome data schizophrenia patient receive treatment long-acting injectable , tablet , liquid formulation first generation ( conventional ) second generation ( atypical ) antipsychotic medication .</brief_summary>
	<brief_title>A Registry Treatment Adherence Patients With Schizophrenia</brief_title>
	<detailed_description>Recent study suggest superior effectiveness second generation ( atypical ) antipsychotic medication first generation ( conventional ) antipsychotic prevent relapse treatment schizophrenia . It estimate majority patient schizophrenia difficulty adhere daily regimen oral medication , use long-acting injectable antipsychotic show increase compliance . This study include retrospective prospective observation treatment outcomes associate antipsychotic drug therapy well characteristic patient population . The study product specific include patient use therapy long-acting injectable , tablet , liquid formulation conventional atypical antipsychotic medication . All patient enroll study start treatment new antipsychotic medication , use accord product label local country . Retrospective data , collect minimum 12 month , include patient diagnosis , age , sex , history treatment antipsychotic medication , hospitalization , Clinical Global Impression severity disease ( CGI-severity ) , Global Assessment Functioning ( GAF ) , reason start new antipsychotic treatment . Prospective data , collect every 3 month 2 year , evaluate assess effectiveness treatment include patient 's adherence antipsychotic medication , CGI-severity , GAF , clinical deterioration patient 's condition . The study investigator enters data registry either electronically paper record form . Safety assessment include incidence , type severity adverse event throughout prospective phase study . Atypical conventional antipsychotic , tablet , liquid injectable formulation prescribe</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patients start treatment new antipsychotic medication , accordance product label local country Permitted physician patient participate clinical trial Patients meet inclusion criterion entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Risperidone long-acting injection</keyword>
	<keyword>Antipsychotic medication</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Treatment retention</keyword>
	<keyword>Observational study</keyword>
</DOC>